Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

NCT03468751 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Henlix, Inc